<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01650259</url>
  </required_header>
  <id_info>
    <org_study_id>1218.95</org_study_id>
    <nct_id>NCT01650259</nct_id>
  </id_info>
  <brief_title>Long-term Daily Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus</brief_title>
  <official_title>Post Marketing Surveillance on Long Term Drug Use of Trazenta® Tablets in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to investigate the safety and efficacy of long-term daily use of Trazenta® Tablets as
      monotherapy in patients with type 2 diabetes mellitus and to assess baseline characteristics
      of patients with type 2 diabetes mellitus starting Trazenta® Tablets or any other oral
      antidiabetic monotherapy (naïve or switched from prior therapy of different oral antidiabetic
      drug).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 23, 2012</start_date>
  <completion_date type="Actual">September 5, 2017</completion_date>
  <primary_completion_date type="Actual">September 5, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse drug reactions (ADRs)</measure>
    <time_frame>up to 156 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The change from the baseline in HbA1c to the last-observation on treatment</measure>
    <time_frame>up to 156 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">4876</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Oral antidiabetic drug (OAD)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Trazenta</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OAD</intervention_name>
    <description>OAD except Trazenta tablets</description>
    <arm_group_label>Oral antidiabetic drug (OAD)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trazenta</intervention_name>
    <description>Linagliptin</description>
    <arm_group_label>Trazenta</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        3300
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Male and female patients with type 2 Diabetes Mellitus who have never been treated
             with Trazenta tablets / Linagliptin (monotherapy) before enrollment. (Trazenta group)

          -  Patients with type 2 Diabetes Mellitus starting any other oral antidiabetic
             monotherapy (naïve or switched from prior therapy of different oral antidiabetic drug
             (OAD)) except Trazenta tablets. (OAD group)

        Exclusion criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTMS MIGRATION CENTER representing all obvious CTMS Dummy Sites</name>
      <address>
        <city>Ingelheim am Rhein</city>
        <zip>55216</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2012</study_first_submitted>
  <study_first_submitted_qc>July 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2012</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

